BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, Crowell K, Eisen DB, Gottlieb AB, Hamzavi I, Hazen PG, Jaleel T, Kimball AB, Kirby J, Lowes MA, Micheletti R, Miller A, Naik HB, Orgill D, Poulin Y. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Journal of the American Academy of Dermatology 2019;81:91-101. [DOI: 10.1016/j.jaad.2019.02.068] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 19.3] [Reference Citation Analysis]
Number Citing Articles
1 Manfredini M, Garbarino F, Bigi L, Pellacani G, Magnoni C. Surgical and postsurgical wound care in hidradenitis suppurativa. Dermatologic Therapy 2020;33. [DOI: 10.1111/dth.13282] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Svoboda RM, Nawaz N, Zaenglein AL. Hormonal Treatment of Acne and Hidradenitis Suppurativa in Adolescent Patients. Dermatologic Clinics 2022. [DOI: 10.1016/j.det.2021.12.004] [Reference Citation Analysis]
3 Westerkam LL, Tackett KJ, Sayed CJ. Comparing the Effectiveness and Safety Associated With Infliximab vs Infliximab-abda Therapy for Patients With Hidradenitis Suppurativa. JAMA Dermatol 2021;157:708-11. [PMID: 33825849 DOI: 10.1001/jamadermatol.2021.0220] [Reference Citation Analysis]
4 Lukac D, Pagani K, Yi JZ, McGee JS. Consulting 'Dr YouTube': a content analysis of YouTube® videos related to hidradenitis suppurativa treatments. Clin Exp Dermatol 2021. [PMID: 34767665 DOI: 10.1111/ced.15017] [Reference Citation Analysis]
5 Schneeweiss MC, Kim SC, Wyss R, Jin Y, Chin K, Merola JF, Mostaghimi A, Silverberg JI, Schneeweiss S. Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases. JAMA Dermatol 2021;157:805-16. [PMID: 34037662 DOI: 10.1001/jamadermatol.2021.1570] [Reference Citation Analysis]
6 Dastoli S, Nisticò SP, Morrone P, Patruno C, Leo A, Citraro R, Gallelli L, Russo E, De Sarro G, Bennardo L. Colchicine in Managing Skin Conditions: A Systematic Review. Pharmaceutics 2022;14:294. [DOI: 10.3390/pharmaceutics14020294] [Reference Citation Analysis]
7 McLean D, McBride O, Samardzic T, Sisic M, Dellavalle RP, Tan J. Impact of a hidradenitis suppurativa patient decision aid on treatment decision making: A randomized controlled trial. JAAD Int 2020;1:190-9. [PMID: 34409339 DOI: 10.1016/j.jdin.2020.09.001] [Reference Citation Analysis]
8 Gupta MA, Vujcic B, Sheridan AD, Gupta AK. Reduced risk of suicidal behaviours associated with the treatment of hidradenitis suppurativa with tumour necrosis factor alpha antagonists: results from the US FDA Adverse Events Reporting System pharmacovigilance database. J Eur Acad Dermatol Venereol 2020;34:1564-8. [PMID: 31981260 DOI: 10.1111/jdv.16224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Lowe MM, Naik HB, Clancy S, Pauli M, Smith KM, Bi Y, Dunstan R, Gudjonsson JE, Paul M, Harris H, Kim E, Shin US, Ahn R, Liao W, Hansen SL, Rosenblum MD. Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-α therapy. JCI Insight 2020;5:139932. [PMID: 32841223 DOI: 10.1172/jci.insight.139932] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
10 Narla S, Price KN, Sachdeva M, Shah M, Shi V, Hamzavi I, Alavi A, Lowes MA. Proceeding report of the Fourth Symposium on Hidradenitis Suppurativa Advances 2019. J Am Acad Dermatol 2021;84:120-9. [PMID: 32497690 DOI: 10.1016/j.jaad.2020.05.114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Karvar M, Panayi AC, Alavi A, Baziar Z, Orgill DP. Trends in the management of hidradenitis suppurativa in the Middle East region: a systematic review. Int J Dermatol 2020. [PMID: 33615455 DOI: 10.1111/ijd.15293] [Reference Citation Analysis]
12 Sherman S, Kridin K, Bitan DT, Leshem YA, Hodak E, Cohen AD. Hidradenitis suppurativa and atopic dermatitis: A 2-way association. J Am Acad Dermatol 2020:S0190-9622(20)33250-3. [PMID: 33378660 DOI: 10.1016/j.jaad.2020.12.051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ghanian S, Yamanaka-Takaichi M, Naik HB, Alavi A. Medical Management of Hidradenitis Suppurativa with Non-Biologic Therapy: What's New? Am J Clin Dermatol 2022. [PMID: 34990004 DOI: 10.1007/s40257-021-00667-8] [Reference Citation Analysis]
14 Ghias MH, Johnston AD, Kutner AJ, Micheletti RG, Hosgood HD, Cohen SR. High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa. Journal of the American Academy of Dermatology 2020;82:1094-101. [DOI: 10.1016/j.jaad.2019.09.071] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
15 Amat-Samaranch V, Agut-Busquet E, Vilarrasa E, Puig L. New perspectives on the treatment of hidradenitis suppurativa. Ther Adv Chronic Dis 2021;12:20406223211055920. [PMID: 34840709 DOI: 10.1177/20406223211055920] [Reference Citation Analysis]
16 Seyed Jafari SM, Hunger RE, Schlapbach C. Hidradenitis Suppurativa: Current Understanding of Pathogenic Mechanisms and Suggestion for Treatment Algorithm. Front Med (Lausanne) 2020;7:68. [PMID: 32195261 DOI: 10.3389/fmed.2020.00068] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
17 Babbush KM, Andriano TM, Cohen SR. Antiandrogen therapy in hidradenitis suppurativa: finasteride for females. Clin Exp Dermatol 2021. [PMID: 34260109 DOI: 10.1111/ced.14847] [Reference Citation Analysis]
18 Onasanya J, Beach RA. A case report about adalimumab-induced radiologically isolated syndrome: A significant side effect of tumour necrosis factor inhibitors. SAGE Open Med Case Rep 2021;9:2050313X211003057. [PMID: 33796317 DOI: 10.1177/2050313X211003057] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Ogunleye AA, Ndem IE, Bui H, Sayed CJ. Vulvoperineal Hidradenitis Suppurativa: Diagnosis, Treatment, and Management of Deformities. Obstet Gynecol Surv 2021;76:644-53. [PMID: 34724076 DOI: 10.1097/OGX.0000000000000944] [Reference Citation Analysis]
20 Gulliver W, Alavi A, Wiseman MC, Gooderham MJ, Rao J, Alam MS, Papp KA, Desjardins O, Jean C. Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study. J Eur Acad Dermatol Venereol 2021. [PMID: 34378812 DOI: 10.1111/jdv.17598] [Reference Citation Analysis]
21 Garelik J, Babbush K, Ghias M, Cohen SR. Efficacy of high-dose intralesional triamcinolone for hidradenitis suppurativa. Int J Dermatol 2021;60:217-21. [PMID: 32808305 DOI: 10.1111/ijd.15124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Hayashi N, Hayama K, Takahashi K, Kurokawa I, Okazaki M, Kashiwagi T, Iwashita E, Terui T. Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan. J Dermatol 2022. [PMID: 35040156 DOI: 10.1111/1346-8138.16297] [Reference Citation Analysis]
23 Langan EA, Recke A, Bokor-Billmann T, Billmann F, Kahle BK, Zillikens D. The Role of the Cutaneous Microbiome in Hidradenitis Suppurativa-Light at the End of the Microbiological Tunnel. Int J Mol Sci 2020;21:E1205. [PMID: 32054085 DOI: 10.3390/ijms21041205] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
24 Aarts P, Dudink K, Vossen ARJV, van Straalen KR, Ardon CB, Prens EP, van der Zee HH. Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa. Drugs 2021;81:1397-410. [PMID: 34283386 DOI: 10.1007/s40265-021-01566-2] [Reference Citation Analysis]
25 Collier EK, Seivright JR, Shi VY, Hsiao JL. Pregnancy and breastfeeding in hidradenitis suppurativa: A review of medication safety. Dermatol Ther 2021;34:e14674. [PMID: 33320387 DOI: 10.1111/dth.14674] [Reference Citation Analysis]
26 Tsentemeidou A, Sotiriou E, Vakirlis E, Sideris N, Lallas A, Ioannides D. Treatment strategies for hidradenitis suppurativa: real-life data from a tertiary Greek hospital. Arch Dermatol Res 2020. [PMID: 33094412 DOI: 10.1007/s00403-020-02150-6] [Reference Citation Analysis]
27 Schell SL, Schneider AM, Nelson AM. Yin and Yang: A disrupted skin microbiome and an aberrant host immune response in hidradenitis suppurativa. Exp Dermatol 2021. [PMID: 34018644 DOI: 10.1111/exd.14398] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Lewandowski M, Świerczewska Z, Barańska‐rybak W. Hidradenitis suppurativa: a review of current treatment options. Int J Dermatology. [DOI: 10.1111/ijd.16115] [Reference Citation Analysis]
29 Kamat D, Gaba S, Kumaran MS. Clinico-Epidemiological Characteristics of Hidradenitis Suppurativa: A Retrospective Cohort Study from a Tertiary Care Centre in Northern India. Indian Dermatol Online J 2021;12:561-5. [PMID: 34430460 DOI: 10.4103/idoj.IDOJ_743_20] [Reference Citation Analysis]
30 Flood KS, Porter ML, Kimball AB. A visit guide for hidradenitis suppurativa-Managing a complex disease in a busy clinic. J Am Acad Dermatol 2021;84:e155-60. [PMID: 33010310 DOI: 10.1016/j.jaad.2020.09.076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Greydanus DE, Azmeh R, Cabral MD, Dickson CA, Patel DR. Acne in the first three decades of life: An update of a disorder with profound implications for all decades of life. Dis Mon 2021;67:101103. [PMID: 33041056 DOI: 10.1016/j.disamonth.2020.101103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
32 Constantinou CA, Fragoulis GE, Nikiphorou E. Hidradenitis suppurativa: infection, autoimmunity, or both? Ther Adv Musculoskelet Dis 2019;11:1759720X19895488. [PMID: 31908656 DOI: 10.1177/1759720X19895488] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Sivanand A, Gulliver WP, Josan CK, Alhusayen R, Fleming PJ. Weight Loss and Dietary Interventions for Hidradenitis Suppurativa: A Systematic Review. J Cutan Med Surg 2020;24:64-72. [PMID: 31502868 DOI: 10.1177/1203475419874412] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
34 van Straalen KR, Tzellos T, Guillem P, Benhadou F, Cuenca-Barrales C, Daxhelet M, Daoud M, Efthymiou O, Giamarellos-Bourboulis EJ, Jemec GBE, Katoulis AC, Koenig A, Lazaridou E, Marzano AV, Matusiak Ł, Molina-Leyva A, Moltrasio C, Pinter A, Potenza C, Romaní J, Saunte DM, Skroza N, Stergianou D, Szepietowski J, Trigoni A, Vilarrasa E, van der Zee HH. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study. J Am Acad Dermatol 2021;85:369-78. [PMID: 33484766 DOI: 10.1016/j.jaad.2020.12.089] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
35 Kitts S, Govea R, Maczuga S, Kirby J. Long-term antibiotic use for the treatment of hidradenitis suppurativa consistent with guideline recommendations. Clin Exp Dermatol 2021;46:582-3. [PMID: 33202036 DOI: 10.1111/ced.14512] [Reference Citation Analysis]
36 Ramos-Rodríguez D, Garcias-Ladaria J, Serra Soler G, Martín-Santiago A. Hidradenitis suppurativa in a transgender man. Clin Exp Dermatol 2021. [PMID: 33852750 DOI: 10.1111/ced.14680] [Reference Citation Analysis]
37 Scala E, Cacciapuoti S, Garzorz-Stark N, Megna M, Marasca C, Seiringer P, Volz T, Eyerich K, Fabbrocini G. Hidradenitis Suppurativa: Where We Are and Where We Are Going. Cells 2021;10:2094. [PMID: 34440863 DOI: 10.3390/cells10082094] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Elston DM. Opportunities for better outcomes in patients with hidradenitis suppurativa. J Am Acad Dermatol 2021;84:1247-8. [PMID: 32771541 DOI: 10.1016/j.jaad.2020.08.002] [Reference Citation Analysis]
39 Choi E, Ooi XT, Chandran NS. Hidradenitis suppurativa in pediatric patients. J Am Acad Dermatol 2020:S0190-9622(20)32436-1. [PMID: 32822788 DOI: 10.1016/j.jaad.2020.08.045] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
40 Fania L, Clemente A, Sampogna F, Mazzanti C, Pallotta S, Panebianco A, Sordi D, Caggiati A, Cassotta G, Tiezzi A, Cristiano L, Zecchi V, Napolitano M, Abeni D. Intralesional ultrasound‐guided combined treatment with triamcinolone plus lincomycin in hidradenitis suppurativa: A pilot study. Dermatologic Therapy 2020;33. [DOI: 10.1111/dth.13901] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Akoglu G, Yildiz I, Karaismailoğlu E, Esme P. Disease severity and poor mental health are the main predictors of stigmatization in patients with hidradenitis suppurativa. Dermatol Ther 2021;34:e14910. [PMID: 33619860 DOI: 10.1111/dth.14910] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Ghias MH, Hyde MJ, Tomalin LE, Morgan BP, Alavi A, Lowes MA, Piguet V. Role of the Complement Pathway in Inflammatory Skin Diseases: A Focus on Hidradenitis Suppurativa. J Invest Dermatol 2020;140:531-536.e1. [PMID: 31870626 DOI: 10.1016/j.jid.2019.09.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
43 Choi ECE, Phan PHC, Oon HH. Hidradenitis suppurativa: racial and socioeconomic considerations in management. Int J Dermatol 2022. [PMID: 35333408 DOI: 10.1111/ijd.16163] [Reference Citation Analysis]
44 Țarcă E, Cojocaru E, Caba B, Luca AC, Roșu ST, Țarcă V, Stătescu L, Chiriac A, Lupu VV, Moroșan E, Trandafir L. Multidisciplinary Management of Adolescents with Hidradenitis Suppurativa - Series of Cases and Literature Review. J Multidiscip Healthc 2021;14:2205-16. [PMID: 34429610 DOI: 10.2147/JMDH.S324325] [Reference Citation Analysis]
45 Cramer P, Schneider-Burrus S, Kovács M, Scholl L, Podda M, Bechara FG. [Hidradenitis suppurativa /acne inversa-surgical options, reconstruction and combinations with drug therapies-an update]. Hautarzt 2021;72:692-9. [PMID: 34228137 DOI: 10.1007/s00105-021-04864-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Finstad A, Lee A, George R, Alhusayen R. Exploring Access to Surgical Interventions for Hidradenitis Suppurativa: Retrospective Population-Based Analysis. JMIR Dermatol 2021;4:e31047. [DOI: 10.2196/31047] [Reference Citation Analysis]
47 Balcere A, Upeniece I, Snipe K, Jezupovs A. Hidradenitis suppurativa in surgeons' practice: Prevalence and treatment approach according to the Hurley stage in Latvia. Dermatol Ther 2021;34:e14687. [PMID: 33331018 DOI: 10.1111/dth.14687] [Reference Citation Analysis]
48 Frew JW. Hidradenitis suppurativa is an autoinflammatory keratinization disease: A review of the clinical, histologic, and molecular evidence. JAAD Int 2020;1:62-72. [PMID: 34409324 DOI: 10.1016/j.jdin.2020.05.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Taylor EM, Hamaguchi R, Kramer KM, Kimball AB, Orgill DP. Plastic Surgical Management of Hidradenitis Suppurativa. Plast Reconstr Surg 2021;147:479-91. [PMID: 33620946 DOI: 10.1097/PRS.0000000000007677] [Reference Citation Analysis]
50 Molinelli E, Sapigni C, Campanati A, Brisigotti V, Offidani A. Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa. Expert Opin Drug Metab Toxicol 2020;16:1019-37. [PMID: 32896186 DOI: 10.1080/17425255.2020.1810233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Sayed CJ, Hsiao JL, Okun MM; Hidradenitis Suppurativa Foundation Women's Health Subcommittee. Clinical Epidemiology and Management of Hidradenitis Suppurativa. Obstet Gynecol 2021;137:731-46. [PMID: 33706337 DOI: 10.1097/AOG.0000000000004321] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Taylor MT, Orenstein LAV, Barbieri JS. Pain Severity and Management of Hidradenitis Suppurativa at US Emergency Department Visits. JAMA Dermatol 2021;157:115-7. [PMID: 33206135 DOI: 10.1001/jamadermatol.2020.4494] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Orenstein LAV, Nguyen TV, Damiani G, Sayed C, Jemec GBE, Hamzavi I. Medical and Surgical Management of Hidradenitis Suppurativa: A Review of International Treatment Guidelines and Implementation in General Dermatology Practice. Dermatology 2020;236:393-412. [PMID: 32408306 DOI: 10.1159/000507323] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
54 Hamad J, McCormick BJ, Sayed CJ, Paci K, Overton M, Daubert T, Figler BD. Multidisciplinary Update on Genital Hidradenitis Suppurativa: A Review. JAMA Surg 2020;155:970-7. [PMID: 32838413 DOI: 10.1001/jamasurg.2020.2611] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Manfredini M, Garbarino F, Bigi L, Pellacani G, Magnoni C. Hidradenitis Suppurativa: Surgical and Postsurgical Management. Skin Appendage Disord 2020;6:195-201. [PMID: 32903939 DOI: 10.1159/000507297] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Narla S, Azzam M, Townsend S, Vellaichamy G, Marzano AV, Alavi A, Lowes MA, Hamzavi IH. Identifying key components and therapeutic targets of the immune system in hidradenitis suppurativa with an emphasis on neutrophils. Br J Dermatol 2021;184:1004-13. [PMID: 32893875 DOI: 10.1111/bjd.19538] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
57 Bechara FG, Podda M, Prens EP, Horváth B, Giamarellos-Bourboulis EJ, Alavi A, Szepietowski JC, Kirby J, Geng Z, Jean C, Jemec GBE, Zouboulis CC. Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: The SHARPS Randomized Clinical Trial. JAMA Surg 2021;156:1001-9. [PMID: 34406349 DOI: 10.1001/jamasurg.2021.3655] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Collier EK, Parvataneni RK, Lowes MA, Naik HB, Okun M, Shi VY, Hsiao JL. Diagnosis and management of hidradenitis suppurativa in women. Am J Obstet Gynecol 2021;224:54-61. [PMID: 32980357 DOI: 10.1016/j.ajog.2020.09.036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Price KN, Thompson AM, Rizvi O, Hendricks AJ, Alavi A, Hsiao JL, Shi VY. Complementary and Alternative Medicine Use in Patients With Hidradenitis Suppurativa. JAMA Dermatol 2020;156:345-8. [PMID: 31995122 DOI: 10.1001/jamadermatol.2019.4595] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
60 Melendez-Gonzalez MDM, Hamad J, Sayed C. Golimumab for the Treatment of Hidradenitis Suppurativa in Patients with Previous TNF-α Treatment Failure. J Invest Dermatol 2021;141:2975-9. [PMID: 34097922 DOI: 10.1016/j.jid.2021.04.026] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Hwang J, Rick J, Hsiao J, Hamzavi IH, Shi VY. Microbiome in Hidradenitis Suppurativa: Current Evidence and Practice. Curr Derm Rep. [DOI: 10.1007/s13671-021-00349-y] [Reference Citation Analysis]
62 Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Current and emerging treatments. J Am Acad Dermatol 2020;82:1061-82. [PMID: 31604100 DOI: 10.1016/j.jaad.2019.08.089] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
63 Collier EK, Price KN, Grogan T, Fernandez JM, Seivright JR, Alhusayen R, Alavi A, Hamzavi IH, Lowes MA, Porter MJ, Shi VY, Hsiao JL. Provider perspectives on the management of hidradenitis suppurativa in pregnancy - A survey study. Int J Womens Dermatol 2021;7:346-8. [PMID: 34222596 DOI: 10.1016/j.ijwd.2020.12.002] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Gáspár K, Hunor Gergely L, Jenei B, Wikonkál N, Kinyó Á, Szegedi A, Remenyik É, Kiss N, Jin X, Sárdy M, Beretzky Z, Péntek M, Gulácsi L, Bánvölgyi A, Brodszky V, Rencz F. Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study. Expert Review of Pharmacoeconomics & Outcomes Research. [DOI: 10.1080/14737167.2021.1895753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
65 Montero-Vilchez T, Salvador-Rodriguez L, Sanchez-Diaz M, Cuenca-Barrales C, Martinez-Lopez A, Arias-Santiago S, Molina-Leyva A. Clinical selection criteria in new clinical trials of hidradenitis suppurativa: External validity and implications on the daily clinical practice. Dermatol Ther 2020;33:e14254. [PMID: 32860480 DOI: 10.1111/dth.14254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]